The USFDA has provided its approval to Aurobindo Pharma for manufacturing and marketing Rivastigmine Tartrate Capsules USP that is used for the treatment of dementia disease, in the American market.

Aurobindo Pharma has said in a BSE filing that “The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.”

According to the company, this product is expected to be launched in the first quarter of next fiscal.

Read EquityPandit’s Technical Analysis on Nifty Pharma